GlassScriptPhysician profile
Aruna Prattipati
NPI 1609828367
$6,824.61
in general payments reported to CMS, 2019-2025
46 companies · $13.55 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $1,382 · 2021: $1,642 · 2022: $1,834 · 2023: $533 · 2025: $13.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.71 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,324.45 | 2019-2023 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $647.45 | 2020-2023 | |
| Amarin Pharma, INC. | $411.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $394.10 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $366.66 | 2019-2023 | |
| Lilly USA, LLC | $359.51 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $346.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.07 | 2020-2023 | Jardiance, Ofev |
| Allergan, INC. | $260.98 | 2019-2020 | |
| Glaxosmithkline, LLC. | $260.46 | 2019-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $202.99 | 2019-2023 | |
| Dexcom, INC. | $171.38 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $149.06 | 2019-2022 | |
| Astellas Pharma US INC | $129.37 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $126.59 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Prattipati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.